Bacteriotherapy in Breast Cancer
Abstract
:1. Introduction
2. Bacteriotherapy and Enhancing of Human Immunity
3. Anticancer Substances Released by Bacteria
3.1. Bacteriocins in Cancer Therapy
3.1.1. Bovicin HC5
3.1.2. Colicins
3.1.3. Laterosporulin 10
3.1.4. Nisin A
3.2. Bacterial Peptides in Cancer Therapy
3.2.1. Ohmyungsamycins A and B
3.2.2. Azurin
3.2.3. Pep27anal2
3.2.4. Entap
3.2.5. Proximicins
3.2.6. Urukthapelstatin A
3.3. Bacterial Toxins in Cancer Therapy
3.3.1. Diphtheria Toxin
3.3.2. Botulinum Neurotoxin Type A
3.3.3. Exotoxin A
3.3.4. Exotoxin T
3.3.5. Hyaluronidase (HylP)
4. Bacteria as a Carrier for Cancer Therapeutic Agents
4.1. Salmonella Typhimurium
4.2. Listeria Monocytogenes
4.3. Bifidobacterium Longum
4.4. Lactobacillus
5. Conclusions
Author Contributions
Funding
Conflicts of Interest
References
- Darbre, P.D.; Fernandez, M.F. Environmental oestrogens and breast cancer: Long-term low-dose effects of mixtures of various chemical combinations. J. Epidemiol. Community Health 2013, 67, 203–205. [Google Scholar] [CrossRef] [PubMed]
- Barnes, B.B.; Steindorf, K.; Hein, R.; Flesch-Janys, D.; Chang-Claude, J. Population attributable risk of invasive postmenopausal breast cancer and breast cancer subtypes for modifiable and non-modifiable risk factors. Cancer Epidemiol. 2011, 35, 345–352. [Google Scholar] [CrossRef] [PubMed]
- Bray, F.; Ferlay, J.; Soerjomataram, I.; Siegel, R.L.; Torre, L.A.; Jemal, A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2018, 68, 394–424. [Google Scholar] [CrossRef] [PubMed]
- Siegel, R.L.; Ma, J.; Zou, Z.; Jemal, A. Cancer statistics, 2014. CA Cancer J. Clin. 2014, 64, 9–29. [Google Scholar] [CrossRef] [PubMed]
- Siegel, R.L.; Miller, K.D.; Jemal, A. Cancer statistics, 2016. CA Cancer J. Clin. 2016, 66, 7–30. [Google Scholar] [CrossRef]
- Song, S.; Vuai, M.S.; Zhong, M. The role of bacteria in cancer therapy–enemies in the past, but allies at present. Infect. Agents Cancer 2018, 13, 9. [Google Scholar] [CrossRef]
- Langie, S.A.; Koppen, G.; Desaulniers, D.; Al-Mulla, F.; Al-Temaimi, R.; Amedei, A.; Azqueta, A.; Bisson, W.H.; Brown, D.; Brunborg, G. Causes of genome instability: The effect of low dose chemical exposures in modern society. Carcinogenesis 2015, 36, S61–S88. [Google Scholar] [CrossRef]
- Kuno, T.; Tsukamoto, T.; Hara, A.; Tanaka, T. Cancer chemoprevention through the induction of apoptosis by natural compounds. J. Biophys. Chem. 2012, 3, 156–173. [Google Scholar] [CrossRef]
- Lax, A.J. Opinion: Bacterial toxins and cancer—A case to answer? Nat. Rev. Microbiol. 2005, 3, 343–349. [Google Scholar] [CrossRef]
- Caygill, C.P.; Braddick, M.; Hill, M.J.; Knowles, R.L.; Sharp, J.C. The association between typhoid carriage, typhoid infection and subsequent cancer at a number of sites. Eur. J. Cancer Prev. 1995, 4, 187–193. [Google Scholar] [CrossRef]
- Lecuit, M.; Abachin, E.; Martin, A.; Poyart, C.; Pochart, P.; Suarez, F.; Bengoufa, D.; Feuillard, J.; Lavergne, A.; Gordon, J.I.; et al. Immunoproliferative small intestinal disease associated with campylobacter jejuni. N. Engl. J. Med. 2004, 350, 239–248. [Google Scholar] [CrossRef] [PubMed]
- Gupta, P.K.; Tripathi, D.; Kulkarni, S.; Rajan, M.G. Mycobacterium tuberculosis H37Rv infected thp-1 cells induce epithelial mesenchymal transition (EMT) in lung adenocarcinoma epithelial cell line (A549). Cell. Immunol. 2016, 300, 33–40. [Google Scholar] [CrossRef] [PubMed]
- Nath, G.; Gulati, A.K.; Shukla, V.K. Role of bacteria in carcinogenesis, with special reference to carcinoma of the gallbladder. World J. Gastroenterol. 2010, 16, 5395. [Google Scholar] [CrossRef] [PubMed]
- Rosadi, F.; Fiorentini, C.; Fabbri, A. Bacterial protein toxins in human cancers. Pathog. Dis. 2016, 74, ftv105. [Google Scholar] [CrossRef]
- De Spiegeleer, B.; Verbeke, F.; D’Hondt, M.; Hendrix, A.; Van De Wiele, C.; Burvenich, C.; Peremans, K.; De Wever, O.; Bracke, M.; Wynendaele, E. The quorum sensing peptides phrg, csp and edf promote angiogenesis and invasion of breast cancer cells in vitro. PLoS ONE 2015, 10, e0119471. [Google Scholar] [CrossRef]
- Roberts, N.J.; Zhang, L.; Janku, F.; Collins, A.; Bai, R.-Y.; Staedtke, V.; Rusk, A.W.; Tung, D.; Miller, M.; Roix, J.; et al. Intratumoral injection of clostridium novyi-nt spores induces antitumor responses. Sci. Transl. Med. 2014, 6, 249ra111. [Google Scholar] [CrossRef]
- Fujimori, M. Genetically engineered bifidobacterium as a drug delivery system for systemic therapy of metastatic breast cancer patients. Breast Cancer 2006, 13, 27–31. [Google Scholar] [CrossRef]
- Zhao, M.; Yang, M.; Ma, H.; Li, X.; Tan, X.; Li, S.; Yang, Z.; Hoffman, R.M. Targeted therapy with a salmonella typhimurium leucine-arginine auxotroph cures orthotopic human breast tumors in nude mice. Cancer Res. 2006, 66, 7647–7652. [Google Scholar] [CrossRef]
- Nauts, H.C.; Swift, W.E.; Coley, B.L. The treatment of malignant tumors by bacterial toxins as developed by the late William B. Coley, M.D., reviewed in the light of modern research. Cancer Res. 1946, 6, 205–216. [Google Scholar]
- Wiemann, B.; Starnes, C.O. Coley’s toxins, tumor necrosis factor and cancer research: A historical perspective. Pharmacol. Ther. 1994, 64, 529–564. [Google Scholar] [CrossRef]
- McCarthy, E.F. The toxins of William B. Coley and the treatment of bone and soft-tissue sarcomas. Iowa Orthop. J. 2006, 26, 154–158. [Google Scholar] [PubMed]
- Gontero, P.; Bohle, A.; Malmstrom, P.-U.; O’Donnell, M.A.; Oderda, M.; Sylvester, R.; Witjes, F. The role of bacillus calmette-guérin in the treatment of non-muscle-invasive bladder cancer. Eur. Urol. 2010, 57, 410–429. [Google Scholar] [CrossRef] [PubMed]
- Zlotta, A.R.; Fleshner, N.E.; Jewett, M.A. The management of BCG failure in non-muscle-invasive bladder cancer: An update. Can. Urol. Assoc. J. 2009, 3, S199–S205. [Google Scholar] [CrossRef] [PubMed]
- Danino, T.; Prindle, A.; Hasty, J.; Bhatia, S. Measuring growth and gene expression dynamics of tumor-targeted S. typhimurium bacteria. J. Vis. Exp. 2013, 77, e50540. [Google Scholar] [CrossRef] [PubMed]
- Alatrash, G.; Jakher, H.; Stafford, P.D.; Mittendorf, E.A. Cancer immunotherapies, their safety and toxicity. Expert Opin. Drug Saf. 2013, 12, 631–645. [Google Scholar] [CrossRef]
- Micallef, I.N.; Stiff, P.J.; Nademanee, A.P.; Maziarz, R.T.; Horwitz, M.E.; Stadtmauer, E.A.; Kaufman, J.L.; McCarty, J.M.; Vargo, R.; Cheverton, P.D. Plerixafor plus granulocyte colony-stimulating factor for patients with non-hodgkin lymphoma and multiple myeloma: Long-term follow-up report. Biol. Blood Marrow Transplant. 2018, 24, 1187–1195. [Google Scholar] [CrossRef]
- Perera, L.P.; Zhang, M.; Nakagawa, M.; Petrus, M.N.; Maeda, M.; Kadin, M.E.; Waldmann, T.A.; Perera, P.Y. Chimeric antigen receptor modified T cells that target chemokine receptor CCR4 as a therapeutic modality for T-cell malignancies. Am. J. Hematol. 2017, 92, 892–901. [Google Scholar] [CrossRef]
- Zlotnik, A. Chemokines and cancer. Int. J. Cancer 2006, 119, 2026–2029. [Google Scholar] [CrossRef]
- Sharma, P.; Allison, J.P. The future of immune checkpoint therapy. Science 2015, 348, 56–61. [Google Scholar] [CrossRef]
- Toldra, J.; Lloris, R.; Carceller, V. American Association for Cancer Research. In Proceedings of the American Association for Cancer Research (AACR)-110th Annual Meeting, Atlanta, GA, USA, 29 March–3 April 2019; pp. 0377–8282. [Google Scholar]
- Chiriva-Internati, M.; Bot, A. A new era in cancer immunotherapy: Discovering novel targets and reprogramming the immune system. Int. Rev. Immunol. 2015, 34, 101–103. [Google Scholar] [CrossRef]
- Zugazagoitia, J.; Guedes, C.; Ponce, S.; Ferrer, I.; Molina-Pinelo, S.; Paz-Ares, L. Current challenges in cancer treatment. Clin. Ther. 2016, 38, 1551–1566. [Google Scholar] [CrossRef] [PubMed]
- Weiner, L.M. Cancer immunology for the clinician. Clin. Adv. Hematol. 2015, 13, 299–306. [Google Scholar]
- Tartari, F.; Santoni, M.; Burattini, L.; Mazzanti, P.; Onofri, A.; Berardi, R. Economic sustainability of anti-pd-1 agents nivolumab and pembrolizumab in cancer patients: Recent insights and future challenges. Cancer Treat. Rev. 2016, 48, 20–24. [Google Scholar] [CrossRef] [PubMed]
- Whiteside, T. The tumor microenvironment and its role in promoting tumor growth. Oncogene 2008, 27, 5904–5912. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Stern, C.; Kasnitz, N.; Kocijancic, D.; Trittel, S.; Riese, P.; Guzman, C.A.; Leschner, S.; Weiss, S. Induction of CD4(+) and CD8(+) anti-tumor effector T cell responses by bacteria mediated tumor therapy. Int. J. Cancer 2015, 137, 2019–2028. [Google Scholar] [CrossRef] [PubMed]
- Na, H.S.; Lee, H.C.; Hong, Y.; Rhee, J.H.; Choy, H.E. Immune response induced by salmonella typhimurium defective in ppgpp synthesis. Vaccine 2006, 24, 2027–2034. [Google Scholar] [CrossRef]
- Phan, T.X.; Nguyen, V.H.; Duong, M.T.; Hong, Y.; Choy, H.E.; Min, J.J. Activation of inflammasome by attenuated salmonella typhimurium in bacteria-mediated cancer therapy. Microbiol. Immunol. 2015, 59, 664–675. [Google Scholar] [CrossRef] [Green Version]
- Lee, H.J.; Kim, H.Y. Lantibiotics, class I bacteriocins from the genus bacillus. J. Microbiol. Biotechnol. 2011, 21, 229–235. [Google Scholar]
- Sahl, H.-G.; Bierbaum, G. Lantibiotics: Biosynthesis and biological activities of uniquely modified peptides from gram-positive bacteria. Annu. Rev. Microbiol. 1998, 52, 41–79. [Google Scholar] [CrossRef]
- Kawai, Y.; Kemperman, R.; Kok, J.; Saito, T. The circular bacteriocins gassericin A and circularin A. Curr. Protein Pept. Sci. 2004, 5, 393–398. [Google Scholar] [CrossRef] [Green Version]
- Van Belkum, M.J.; Martin-Visscher, L.A.; Vederas, J.C. Structure and genetics of circular bacteriocins. Trends Microbiol. 2011, 19, 411–418. [Google Scholar] [CrossRef] [PubMed]
- Karpiński, T.; Szkaradkiewicz, A.; Gamian, A. New enterococcal anticancer peptide. In Proceedings of the 23rd European Congress of Clinical Microbiology and Infectious Diseases, Berlin, Germany, 27–30 April 2013; p. 30. [Google Scholar]
- Kaur, S.; Kaur, S. Bacteriocins as potential anticancer agents. Front. Pharmacol. 2015, 6, 272. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Paiva, A.D.; de Oliveira, M.D.; de Paula, S.O.; Baracat-Pereira, M.C.; Breukink, E.; Mantovani, H.C. Toxicity of bovicin HC5 against mammalian cell lines and the role of cholesterol in bacteriocin activity. Microbiology 2012, 158, 2851–2858. [Google Scholar] [CrossRef] [PubMed]
- Chumchalova, J.; Šmarda, J. Human tumor cells are selectively inhibited by colicins. Folia Microbiol. 2003, 48, 111–115. [Google Scholar] [CrossRef] [PubMed]
- Baindara, P.; Gautam, A.; Raghava, G.; Korpole, S. Anticancer properties of a defensin like class IID bacteriocin laterosporulin10. Sci. Rep. 2017, 7, 46541. [Google Scholar] [CrossRef] [Green Version]
- Begde, D.; Bundale, S.; Mashitha, P.; Rudra, J.; Nashikkar, N.; Upadhyay, A. Immunomodulatory efficacy of nisin—A bacterial lantibiotic peptide. J. Pept. Sci. 2011, 17, 438–444. [Google Scholar] [CrossRef]
- Joo, N.E.; Ritchie, K.; Kamarajan, P.; Miao, D.; Kapila, Y.L. Nisin, an apoptogenic bacteriocin and food preservative, attenuates HNSCC tumorigenesis via CHAC 1. Cancer Med. 2012, 1, 295–305. [Google Scholar] [CrossRef]
- Um, S.; Choi, T.J.; Kim, H.; Kim, B.Y.; Kim, S.-H.; Lee, S.K.; Oh, K.-B.; Shin, J.; Oh, D.-C. Ohmyungsamycins A and B: Cytotoxic and antimicrobial cyclic peptides produced by streptomyces sp. from a volcanic island. J. Org. Chem. 2013, 78, 12321–12329. [Google Scholar] [CrossRef]
- Mohamed, M.S.; Fattah, S.A.; Mostafa, H.M. Azurin as antitumor protein and its effect on the cancer cell lines. Curr. Res. J. Biol. Sci. 2010, 2, 396–401. [Google Scholar]
- Gao, M.; Zhou, J.; Su, Z.; Huang, Y. Bacterial cupredoxin azurin hijacks cellular signaling networks: Protein-protein interactions and cancer therapy. Protein Sci. 2017, 26, 2334–2341. [Google Scholar] [CrossRef] [Green Version]
- Sung, W.S.; Park, Y.; Choi, C.-H.; Hahm, K.-S.; Lee, D.G. Mode of antibacterial action of a signal peptide, Pep27 from streptococcus pneumoniae. Biochem. Biophys. Res. Commun. 2007, 363, 806–810. [Google Scholar] [CrossRef] [PubMed]
- Lee, D.G.; Hahm, K.-S.; Park, Y.; Kim, H.-Y.; Lee, W.; Lim, S.-C.; Seo, Y.-K.; Choi, C.-H. Functional and structural characteristics of anticancer peptide Pep27 analogues. Cancer Cell Int. 2005, 5, 21. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Karpinski, T.M.; Szkaradkiewicz, A.K. Anti-cancer peptides from bacteria. Bangladesh J. Pharmacol. 2013, 8, 343–348. [Google Scholar] [CrossRef]
- Karpiński, T. New Peptide (Entap) with Anti-proliferative Activity Produced by Bacteria of Enterococcus Genus. Post-Doctoral Thesis, Habilitation Thesis, Poznań University of Medical Sciences, Poznań, Poland, 2012. [Google Scholar]
- Fiedler, H.P.; Bruntner, C.; Riedlinger, J.; Bull, A.T.; Knutsen, G.; Goodfellow, M.; Jones, A.; Maldonado, L.; Pathom-aree, W.; Beil, W.; et al. Proximicin A, B and C, novel aminofuran antibiotic and anticancer compounds isolated from marine strains of the actinomycete verrucosispora. J. Antibiot. (Tokyo) 2008, 61, 158–163. [Google Scholar] [CrossRef] [Green Version]
- Matsuo, Y.; Kanoh, K.; Yamori, T.; Kasai, H.; Katsuta, A.; Adachi, K.; Shin-Ya, K.; Shizuri, Y. Urukthapelstatin A, a novel cytotoxic substance from marine-derived mechercharimyces asporophorigenens YM11-542. J. Antibiot. (Tokyo) 2007, 60, 256–260. [Google Scholar] [CrossRef]
- Yamada, T.; Goto, M.; Punj, V.; Zaborina, O.; Chen, M.L.; Kimbara, K.; Majumdar, D.; Cunningham, E.; Das Gupta, T.K.; Chakrabarty, A.M. Bacterial redox protein azurin, tumor suppressor protein p53, and regression of cancer. Proc. Natl. Acad. Sci. USA 2002, 99, 14098–14103. [Google Scholar] [CrossRef] [Green Version]
- Jia, L.; Gorman, G.S.; Coward, L.U.; Noker, P.E.; McCormick, D.; Horn, T.L.; Harder, J.B.; Muzzio, M.; Prabhakar, B.; Ganesh, B.; et al. Preclinical pharmacokinetics, metabolism, and toxicity of azurin-p28 (nsc745104) a peptide inhibitor of p53 ubiquitination. Cancer Chemother. Pharmacol. 2011, 68, 513–524. [Google Scholar] [CrossRef]
- Mehta, R.R.; Yamada, T.; Taylor, B.N.; Christov, K.; King, M.L.; Majumdar, D.; Lekmine, F.; Tiruppathi, C.; Shilkaitis, A.; Bratescu, L.; et al. A cell penetrating peptide derived from azurin inhibits angiogenesis and tumor growth by inhibiting phosphorylation of VEGFR-2, FAK and AKT. Angiogenesis 2011, 14, 355–369. [Google Scholar] [CrossRef]
- Bernardes, N.; Ribeiro, A.S.; Abreu, S.; Mota, B.; Matos, R.G.; Arraiano, C.M.; Seruca, R.; Paredes, J.; Fialho, A.M. The bacterial protein azurin impairs invasion and FAK/ Src signaling in P-cadherin-overexpressing breast cancer cell models. PLoS ONE 2013, 8, e69023. [Google Scholar] [CrossRef] [Green Version]
- Lulla, R.R.; Goldman, S.; Yamada, T.; Beattie, C.W.; Bressler, L.; Pacini, M.; Pollack, I.F.; Fisher, P.G.; Packer, R.J.; Dunkel, I.J.; et al. Phase 1 trial of p28 (NSC745104), a non-HDM2-mediated peptide inhibitor of p53 ubiquitination in pediatric patients with recurrent or progressive central nervous system tumors: A Pediatric Brain Tumor Consortium Study. Neuro-Oncol. 2016, 18, 1319–1325. [Google Scholar] [CrossRef] [Green Version]
- Yamada, T.; Mehta, R.R.; Lekmine, F.; Christov, K.; King, M.L.; Majumdar, D.; Shilkaitis, A.; Green, A.; Bratescu, L.; Beattie, C.W. A peptide fragment of azurin induces a p53-mediated cell cycle arrest in human breast cancer cells. Mol. Cancer Ther. 2009, 8, 2947–2958. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Yamada, T.; Gupta, T.K.D.; Beattie, C.W. P28-Mediated Activation of p53 in G2-M Phase of the Cell Cycle Enhances the Efficacy of DNA Damaging and Antimitotic Chemotherapy. Cancer Res. 2016, 76, 2354–2365. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Lewis, D.J.; Dao, H., Jr.; Nagarajan, P.; Duvic, M. Primary cutaneous anaplastic large-cell lymphoma: Complete remission for 13 years after denileukin diftitox. JAAD Case Rep. 2017, 3, 501–504. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Lutz, M.B.; Baur, A.S.; Schuler-Thurner, B.; Schuler, G. Immunogenic and tolerogenic effects of the chimeric IL-2-diphtheria toxin cytocidal agent Ontak on CD25+ cells. Oncoimmunology 2014, 3, e28223. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Holmes, R.K. Biology and molecular epidemiology of diphtheria toxin and the tox gene. J. Infect. Dis. 2000, 181, 156–167. [Google Scholar] [CrossRef] [Green Version]
- Bandala, C.; Cortés-Algara, A.; Mejía-Barradas, C.; Ilizaliturri-Flores, I.; Dominguez-Rubio, R.; Bazán-Méndez, C.; Floriano-Sánchez, E.; Luna-Arias, J.; Anaya-Ruiz, M.; Lara-Padilla, E. Botulinum neurotoxin type a inhibits synaptic vesicle 2 expression in breast cancer cell lines. Int. J. Clin. Exp. Pathol. 2015, 8, 8411–8418. [Google Scholar]
- Baudelet, C.; Cron, G.O.; Dessy, C.; Martinive, P.; De Wever, J.; Verrax, J.; Beghein, N.; Gr, V.; Calderon, P.B.; Feron, O. Botulinum toxin potentiates cancer radiotherapy and chemotherapy. Clin. Cancer Res. 2006, 12, 1276–1283. [Google Scholar]
- Hemmati, M.; Tarighi, P.; Amoozadeh, S.; Farajollahi, M.M. Expression and purification of the recombinant pseudomonas exotoxin a conjugated to herceptin and its anti-proliferation effects on sk-br-3. In Proceedings of the International Tehran Breast Cancer Congress (TBCC9), Tehran, Iran, 18–20 October 2017. [Google Scholar]
- Bjorn, M.J.; Groetsema, G.; Scalapino, L. Antibody-pseudomonas exotoxin a conjugates cytotoxic to human breast cancer cells in vitro. Cancer Res. 1986, 46, 3262–3267. [Google Scholar]
- Goldufsky, J.; Wood, S.; Hajihossainlou, B.; Rehman, T.; Majdobeh, O.; Kaufman, H.L.; Ruby, C.E.; Shafikhani, S.H. Pseudomonas aeruginosa exotoxin T induces potent cytotoxicity against a variety of murine and human cancer cell lines. J. Med. Microbiol. 2015, 64, 164–173. [Google Scholar] [CrossRef]
- Lee, J.H.; Moore, L.D.; Kumar, S.; Pritchard, D.G.; Ponnazhagan, S.; Deivanayagam, C. Bacteriophage hyaluronidase effectively inhibits growth, migration and invasion by disrupting hyaluronan-mediated Erk1/2 activation and RhoA expression in human breast carcinoma cells. Cancer Lett. 2010, 298, 238–249. [Google Scholar] [CrossRef]
- Murphy, J.R. Mechanism of diphtheria toxin catalytic domain delivery to the eukaryotic cell cytosol and the cellular factors that directly participate in the process. Toxins 2011, 3, 294–308. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Martarelli, D.; Pompei, P.; Mazzoni, G. Inhibition of adrenocortical carcinoma by diphtheria toxin mutant CRM197. Chemotherapy 2009, 55, 425–432. [Google Scholar] [CrossRef] [PubMed]
- Vallera, D.A.; Li, C.; Jin, N.; Panoskaltsis-Mortari, A.; Hall, W.A. Targeting urokinase-type plasminogen activator receptor on human glioblastoma tumors with diphtheria toxin fusion protein DTAT. J. Natl. Cancer Inst. 2002, 94, 597–606. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Tintner, R.; Jankovic, J. Botulinum toxin type a in the management of oromandibular dystonia and bruxism. In Scientific Therapeutic Aspects of Botulinum Toxin Philadelphia PA; Brin Mitchell, F., Ed.; Lippincott Williams & Wilkins: Philadelphia, PA, USA, 2002; pp. 343–350. [Google Scholar]
- de Groot, M.; Toering, S.T.; Boer, K.; Spliet, W.G.; Heimans, J.J.; Aronica, E.; Reijneveld, J.C. Expression of synaptic vesicle protein 2a in epilepsy-associated brain tumors and in the peritumoral cortex. Neuro-Oncol. 2010, 12, 265–273. [Google Scholar] [CrossRef]
- Coelho, A.; Dinis, P.; Pinto, R.; Gorgal, T.; Silva, C.; Silva, A.; Silva, J.; Cruz, C.D.; Cruz, F.; Avelino, A. Distribution of the high-affinity binding site and intracellular target of botulinum toxin type a in the human bladder. Eur. Urol. 2010, 57, 884–890. [Google Scholar] [CrossRef]
- Vogl, C.; Tanifuji, S.; Danis, B.; Daniels, V.; Foerch, P.; Wolff, C.; Whalley, B.J.; Mochida, S.; Stephens, G.J. Synaptic vesicle glycoprotein 2a modulates vesicular release and calcium channel function at peripheral sympathetic synapses. Eur. J. Neurosci. 2015, 41, 398–409. [Google Scholar] [CrossRef]
- Portela-Gomes, G.M.; Lukinius, A.; Grimelius, L. Synaptic vesicle protein 2, a new neuroendocrine cell marker. Am. J. Pathol. 2000, 157, 1299–1309. [Google Scholar] [CrossRef] [Green Version]
- Zhang, Q.; Fan, H.; Shen, J.; Hoffman, R.M.; Xing, H.R. Human breast cancer cell lines co-express neuronal, epithelial, and melanocytic differentiation markers in vitro and in vivo. PLoS ONE 2010, 5, e9712. [Google Scholar] [CrossRef] [Green Version]
- Dong, M.; Yeh, F.; Tepp, W.H.; Dean, C.; Johnson, E.A.; Janz, R.; Chapman, E.R. SV2 is the protein receptor for botulinum neurotoxin A. Science 2006, 312, 592–596. [Google Scholar] [CrossRef]
- Yates, S.P.; Taylor, P.L.; Jørgensen, R.; Ferraris, D.; Zhang, J.; Andersen, G.R.; Merrill, A.R. Structure–function analysis of water-soluble inhibitors of the catalytic domain of exotoxin a from pseudomonas aeruginosa. Biochem. J. 2005, 385, 667–675. [Google Scholar] [CrossRef] [Green Version]
- Wood, S.J.; Goldufsky, J.W.; Bello, D.; Masood, S.; Shafikhani, S.H. Pseudomonas aeruginosa ExoT induces mitochondrial apoptosis in target host cells in a manner that depends on its GTPase-activating protein (GAP) domain activity. J. Biol. Chem. 2015, 290, 29063–29073. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Garrity-Ryan, L.; Shafikhani, S.; Balachandran, P.; Nguyen, L.; Oza, J.; Jakobsen, T.; Sargent, J.; Fang, X.; Cordwell, S.; Matthay, M. The ADP ribosyltransferase domain of pseudomonas aeruginosa ExoT contributes to its biological activities. Infect. Immun. 2004, 72, 546–558. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Murga, C.; Zohar, M.; Teramoto, H.; Gutkind, J.S. Rac1 and RhoG promote cell survival by the activation of PI3K and Akt, independently of their ability to stimulate JNK and NF-kappaB. Oncogene 2002, 21, 207–216. [Google Scholar] [CrossRef] [PubMed]
- Feng, Y.X.; Zhao, J.S.; Li, J.J.; Wang, T.; Cheng, S.Q.; Yuan, Y.; Wang, F.; Wang, X.F.; Xie, D. Liver cancer: EphrinA2 promotes tumorigenicity through rac1/Akt/NF-kappaB signaling pathway. Hepatology 2010, 51, 535–544. [Google Scholar] [CrossRef]
- Aaltomaa, S.; Lipponen, P.; Tammi, R.; Tammi, M.; Viitanen, J.; Kankkunen, J.-P.; Kosma, V.-M. Strong stromal hyaluronan expression is associated with psa recurrence in local prostate cancer. Urol. Int. 2002, 69, 266–272. [Google Scholar] [CrossRef]
- Lokeshwar, V.B.; Rubinowicz, D.; Schroeder, G.L.; Forgacs, E.; Minna, J.D.; Block, N.L.; Nadji, M.; Lokeshwar, B.L. Stromal and epithelial expression of tumor markers hyaluronic acid and HYAL1 hyaluronidase in prostate cancer. J. Biol. Chem. 2001, 276, 11922–11932. [Google Scholar] [CrossRef] [Green Version]
- Udabage, L.; Brownlee, G.R.; Nilsson, S.K.; Brown, T.J. The over-expression of HAS2, HYAL-2 and CD44 is implicated in the invasiveness of breast cancer. Exp. Cell Res. 2005, 310, 205–217. [Google Scholar] [CrossRef]
- Camenisch, T.D.; Spicer, A.P.; Brehm-Gibson, T.; Biesterfeldt, J.; Augustine, M.L.; Calabro, A.; Kubalak, S.; Klewer, S.E.; McDonald, J.A. Disruption of hyaluronan synthase-2 abrogates normal cardiac morphogenesis and hyaluronan-mediated transformation of epithelium to mesenchyme. J. Clin. Investig. 2000, 106, 349–360. [Google Scholar] [CrossRef] [Green Version]
- Lokeshwar, V.B.; Cerwinka, W.H.; Isoyama, T.; Lokeshwar, B.L. HYAL1 hyaluronidase in prostate cancer: A tumor promoter and suppressor. Cancer Res. 2005, 65, 7782–7789. [Google Scholar] [CrossRef] [Green Version]
- Lee, J.H.; Moore, L.; Kumar, S.; DeLucas, L.; Pritchard, D.; Ponnazhagan, S.; Deivanayagam, C. In vitro studies on anti-cancer effect of Streptococcus pyogenes phage hyaluronidase (HylP) on breast cancer. In Proceedings of the AACR Annual Meeting, San Diego, CA, USA, 12–16 April 2008. [Google Scholar]
- Khan, S.A.; Everest, P.; Servos, S.; Foxwell, N.; Zähringer, U.; Brade, H.; Rietschel, E.T.; Dougan, G.; Charles, I.G.; Maskell, D.J. A lethal role for lipid A in salmonella infections. Mol. Microbiol. 1998, 29, 571–579. [Google Scholar] [CrossRef]
- Pawelek, J.M.; Low, K.B.; Bermudes, D. Tumor-targeted salmonella as a novel anticancer vector. Cancer Res. 1997, 57, 4537–4544. [Google Scholar] [PubMed]
- Clairmont, C.; Lee, K.C.; Pike, J.; Ittensohn, M.; Low, K.B.; Pawelek, J.; Bermudes, D.; Brecher, S.M.; Margitich, D.; Turnier, J.; et al. Biodistribution and genetic stability of the novel antitumor agent VNP20009, a genetically modified strain of Salmonella typhimurium. J. Infect. Dis. 2000, 181, 1996–2002. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Zheng, J.H.; Min, J.-J. Targeted cancer therapy using engineered salmonella typhimurium. Chonnam. Med. J. 2016, 52, 173–184. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Gunn, G.R.; Zubair, A.; Peters, C.; Pan, Z.K.; Wu, T.C.; Paterson, Y. Two Listeria monocytogenes vaccine vectors that express different molecular forms of human papilloma virus-16 (HPV-16) E7 induce qualitatively different T cell immunity that correlates with their ability to induce regression of established tumors immortalized by HPV-16. J. Immunol. 2001, 167, 6471–6479. [Google Scholar]
- Shahabi, V.; Seavey, M.M.; Maciag, P.C.; Rivera, S.; Wallecha, A. Development of a live and highly attenuated listeria monocytogenes-based vaccine for the treatment of Her2/neu-overexpressing cancers in human. Cancer Gene Ther. 2011, 18, 53–62. [Google Scholar] [CrossRef]
- Singh, R.; Dominiecki, M.E.; Jaffee, E.M.; Paterson, Y. Fusion to Listeriolysin O and delivery by Listeria monocytogenes enhances the immunogenicity of HER-2/neu and reveals subdominant epitopes in the FVB/N mouse. J. Immunol. 2005, 175, 3663–3673. [Google Scholar] [CrossRef] [Green Version]
- Liu, C.-F.; Pan, T.-M. In vitro effects of lactic acid bacteria on cancer cell viability and antioxidant activity. J. Food Drug Anal. 2010, 18. [Google Scholar]
- Asoudeh-Fard, A.; Barzegari, A.; Dehnad, A.; Bastani, S.; Golchin, A.; Omidi, Y. Lactobacillus plantarum induces apoptosis in oral cancer KB cells through upregulation of PTEN and downregulation of MAPK signalling pathways. Bioimpacts 2017, 7, 193–198. [Google Scholar] [CrossRef]
- Wang, Y.; Liu, Y.; Malek, S.N.; Zheng, P.; Liu, Y. Targeting HIF1α eliminates cancer stem cells in hematological malignancies. Cell Stem. Cell 2011, 8, 399–411. [Google Scholar] [CrossRef] [Green Version]
- Jesenberger, V.; Procyk, K.J.; Yuan, J.; Reipert, S.; Baccarini, M. Salmonella-induced caspase-2 activation in macrophages: A novel mechanism in pathogenmediated apoptosis. J. Exp. Med. 2000, 192, 1035–1045. [Google Scholar] [CrossRef]
- Gedde, M.M.; Higgins, D.E.; Tilney, L.G.; Portnoy, D.A. Portnoy. Role of listeriolysin o in cell-to-cell spread of listeria monocytogenes. Infect. Immun. 2000, 68, 999–1003. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kim, S.H.; Castro, F.; Paterson, Y.; Gravekamp, C. High efficacy of a listeria-based vaccine against metastatic breast cancer reveals a dual mode of action. Cancer Res. 2009, 69, 5860–5866. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Schell, M.A.; Karmirantzou, M.; Snel, B.; Vilanova, D.; Berger, B.; Pessi, G.; Zwahlen, M.-C.; Desiere, F.; Bork, P.; Delley, M. The genome sequence of bifidobacterium longum reflects its adaptation to the human gastrointestinal tract. Proc. Natl. Acad. Sci. USA 2002, 99, 14422–14427. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Yazawa, K.; Fujimori, M.; Amano, J.; Kano, Y.; Taniguchi, S. Bifidobacterium longum as a delivery system for cancer gene therapy: Selective localization and growth in hypoxic tumors. Cancer Gene Ther. 2000, 7, 269–274. [Google Scholar] [CrossRef] [Green Version]
- Nakamura, T.; Sasaki, T.; Fujimori, M.; Yazawa, K.; Kano, Y.; Amano, J.; Taniguchi, S. Cloned cytosine deaminase gene expression of bifidobacterium longum and application to enzyme/pro-drug therapy of hypoxic solid tumors. Biosci. Biotechnol. Biochem. 2002, 66, 2362–2366. [Google Scholar] [CrossRef] [Green Version]
- Takeuchi, A.; Matsumura, H.; Kano, Y. Cloning and expression in Escherichia coli of a gene, hup, encoding the histone-like protein HU of Bifidobacterium longum. Biosci. Biotechnol. Biochem. 2002, 66, 598–603. [Google Scholar] [CrossRef]
- Landete, J.M.; Rodríguez, H.; Curiel, J.A.; de las Rivas, B.; de Felipe, F.L.; Muñoz, R. Degradation of phenolic compounds found in olive products by lactobacillus plantarum strains. In Olives and Olive Oil in Health and Disease Prevention; Elsevier: Philadelphia, PA, USA, 2010; pp. 387–396. [Google Scholar]
- Kassayova, M.; Bobrov, N.; Strojný, L.; Kiskova, T.; Mikeš, J.; Demečková, V.; Orendáš, P.; Bojkova, B.; Péč, M.; Kubatka, P.; et al. Preventive effects of probiotic bacteria lactobacillus plantarum and dietary fiber in chemically-induced mammary carcinogenesis. Anticancer Res. 2014, 34, 4969–4975. [Google Scholar]
- Hadrup, S.; Donia, M.; Thor Straten, P. Effector CD4 and CD8 T cells and their role in the tumor microenvironment. Cancer Microenviron. 2013, 6, 123–133. [Google Scholar] [CrossRef] [Green Version]
- Gu-Trantien, C.; Loi, S.; Garaud, S.; Equeter, C.; Libin, M.; De Wind, A.; Ravoet, M.; Le Buanec, H.; Sibille, C.; Manfouo-Foutsop, G. CD4+ follicular helper T cell infiltration predicts breast cancer survival. J. Clin. Investig. 2013, 123, 2873–2892. [Google Scholar] [CrossRef]
- Chen, C.; Chan, H.M.; Kubow, S. Kefir extracts suppress in vitro proliferation of estrogen-dependent human breast cancer cells but not normal mammary epithelial cells. J. Med. Food 2007, 10, 416–422. [Google Scholar] [CrossRef]
- Van’t Veer, P.; Van Leer, E.M.; Rietdijk, A.; Kok, F.J.; Schouten, E.G.; Hermus, R.J.; Sturmans, F. Combination of dietary factors in relation to breast-cancer occurrence. Int. J. Cancer 1991, 47, 649–653. [Google Scholar] [CrossRef] [PubMed]
- Rachid, M.; Matar, C.; Duarte, J.; Perdigon, G. Effect of milk fermented with a lactobacillus helveticus R389(+) proteolytic strain on the immune system and on the growth of 4T1 breast cancer cells in mice. Fems. Immunol. Med. Microbiol. 2006, 47, 242–253. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kassayova, M.; Bobrov, N.; Strojný, L.; Orendáš, P.; Demečková, V.; Jendželovský, R.; Kubatka, P.; Kiskova, T.; Kružliak, P.; Adamkov, M.; et al. Anticancer and immunomodulatory effects of lactobacillus plantarum ls/07, inulin and melatonin in nmu-induced rat model of breast cancer. Anticancer Res. 2016, 36, 2719–2728. [Google Scholar] [PubMed]
- Aragon, F.; Carino, S.; Perdigon, G.; de Moreno de LeBlanc, A. Inhibition of growth and metastasis of breast cancer in mice by milk fermented with lactobacillus casei CRL 431. J. Immunother. 2015, 38, 185–196. [Google Scholar] [CrossRef]
- Tabarestani, S.; Ghafouri-Fard, S. Cancer stem cells and response to therapy. Asian Pac. J. Cancer Prev. 2012, 13, 5947–5954. [Google Scholar] [CrossRef] [Green Version]
- Shiozawa, Y.; Nie, B.; Pienta, K.J.; Morgan, T.M.; Taichman, R.S. Cancer stem cells and their role in metastasis. Pharmacol. Ther. 2013, 138, 285–293. [Google Scholar] [CrossRef] [Green Version]
- Keith, B.; Simon, M.C. Hypoxia-inducible factors, stem cells, and cancer. Cell 2007, 129, 465–472. [Google Scholar] [CrossRef] [Green Version]
- Riedl, S.; Zweytick, D.; Lohner, K. Membrane-active host defense peptides–challenges and perspectives for the development of novel anticancer drugs. Chem. Phys. Lipids 2011, 164, 766–781. [Google Scholar] [CrossRef] [Green Version]
- Tørfoss, V.; Isaksson, J.; Ausbacher, D.; Brandsdal, B.O.; Flaten, G.E.; Anderssen, T.; Cavalcanti-Jacobsen, C.d.A.; Havelkova, M.; Nguyen, L.T.; Vogel, H.J.; et al. Improved anticancer potency by head-to-tail cyclization of short cationic anticancer peptides containing a lipophilic β2, 2-amino acid. J. Pept. Sci. 2012, 18, 609–619. [Google Scholar] [CrossRef]
- Deutscher, S.L. Phage display in molecular imaging and diagnosis of cancer. Chem. Rev. 2010, 110, 3196–3211. [Google Scholar] [CrossRef] [Green Version]
Bacteriocins | Source | Breast Cancer Cell Line | Other Human Cancer Cells/Cell Lines | Ref. |
---|---|---|---|---|
Bovicin HC5 | Streptococcus bovis HC5 | MCF-7 | Liver, hepatocellular carcinoma (HepG2) | [44,45] |
Colicin E1 and A | Escherichia coli | MCF7, ZR75, BT549, BT474, MDA-MB-231, SKBR3 and T47D | Osteosarcoma (HOS), fibrosarcoma (MRC5, HS913T), leiomyosarcoma (SKUT-1 cells), lung cancer (A-549, PC-14, RERF-LC-AI), ovarian carcinoma, colon cancer (HCT116) | [44,46] |
Laterosporulin 10 | Brevibacillus sp. strain SKDU10 | MCF-7 | cervical cancer (HeLa), embryonic kidney cancer (HEK293T), fibrosarcoma (HT1080), lung carcinoma (H1299) | [47] |
Nisin A | Lactococcus lactis | MCF-7 | Head and neck squamous cell carcinoma (UM-SCC-17B, UM-SCC-14A, HSC-3), colon cancer (LS180, SW48, HT29, Caco2), liver hepatocellular carcinoma (HepG2), acute T cell leukaemia (Jurkat) | [48] |
Protein/Peptide | Source | Breast Cancer Cell Line | Other Human Cancer Cells/Cell Lines | Ref |
---|---|---|---|---|
Ohmyungsamycins A and B | Streptomyces sp. | MDAMB231 | diverse cancer cells, colon cancer (HCT116), lung cancer cells (A549), stomach cancer (SNU638), liver cancer (SKHEP1) | [50] |
Azurin | Pseudomonas aeruginosa strains | MCF7, ZR-75-1, T47D, MDA-MB-157, MDD2, MDA-MB-231 | Normal melanocytes (HFB4), liver cell line (HEPG2), colon cell line (HCT116), progressive pediatric CNS tumors | [51,52] |
Pep27anal2 | Streptococcus pneumoniae | MCF-7 | leukemia cells (AML-2, HL-60, Jurkat), gastric cancer cells (SNU-601) | [53,54] |
Entap | Enterococus sp. strains | MDA-MB-231 | Gastric adenocarcinoma cells (AGS), uterine cervix adenocarcinoma cells (HeLa), prostate carcinoma (22Rv1), colorectal adenocarcinoma (HT-29) | [43,55,56] |
Proximicins | Verrucosispora sp. MG-37 and AB-18-032 | MCF 7 | Human gastric adenocarcinoma (AGS), human hepatocellular carcinoma (HepG2) | [57] |
Urukthapelstatin A | Mechercharimyces asporophorigenens YM11-542 | MCF-7 | Human lung cancers (A549, DMS114, NCIH460), ovarian cancers (OVCAR-3, OVCAR-4, OVCAR-5, OVCAR-8, SK-OV3), colon cancer (HCT-116) | [58] |
Toxins | Source | Breast Cancer Cell Line | Other Human Cancer Cells/Cell Lines | Ref |
---|---|---|---|---|
Diphtheria toxin | Corynebacterium diphtheria | MCF 7 | Adrenocortical carcinoma (H295R), glioblastomas (U118MG, U373MG, U87MG), cutaneous T cell lymphomas (CTCL), cervical adenocarcinoma (HeLa), colon cancer (SW480, SW620, HCT116, CaCo-2, and HT-29) | [66,67,68] |
Botulinum neurotoxin type A | Clostridium botulinum | T47D, MDA-MB-231, MDA-MB-453 | prostate cancer (PC-3, LNCaP), neuroblastoma (SH-SY5Y) | [69,70] |
Exotoxin A | Pseudomonas aeruginosa | MCF-7, BT-20, CAMA-1, SKBR-3 | pancreatic cancer (PaCa-2), melanomas (FEMX, Melmet-1, Melmet-5, Melmet-44, MelRM, MM200), head and neck squamous carcinomas, Burkitt’s lymphoma (Daudi, CA46), leukemias (EHEB, MEC1) | [71,72] |
Exotoxin T | Pseudomonas aeruginosa | MDA-MB-231, EMT6, 4T1 | murine-derived fibrosarcoma cell line (MCA-205), human melanoma (A375), human lung adenocarcinoma (Calu-3), murine lung carcinoma (LLC1), human ovarian adenocarcinoma (SK-OV-3), human cervical adenocarcinoma (HeLa) | [73] |
Hyaluronidases (Hyals) | Streptococcus pyogenes | Hs578T, MDA-MB-231, MCF-7 | [74] |
Bacteria as a Carrier | Source | Breast Cancer Cell Line | Other Human Cancer Cells/Cell Lines | Clinical Phase | Ref |
---|---|---|---|---|---|
Salmonella typhimurium (VNP20009) | Salmonella | MDA-MB-435, MDA-MB-361, MDA-MB-231, 4T1, Caco2, RKO, and MCF7 | Metastatic melanoma (MDA-MB-435, B16-F10), human glioblastoma (U87MG), human pancreatic cancer (ASPC-1), colon carcinoma (WiDr, CT26) | Phase I | [97,98,99] |
Listeriolysin O (Lm-LLO-E7) | Listeria monocytogenes | 4T1, MDA-MB-231 | Cervical cancer, human acute monocytic leukemia cell line THP-1, human ovarian cancer (SKOV3-A2), human prostate cancer (LNCaP), and human colon cancer (Colo205) | Phase I/II | [100] |
Listeriolysin O (ADXS31-142) | Listeria monocytogenes | EMT6-Luc | Prostate cancer, breast cancer, colorectal cancer, pancreatic cancers(EMT6-Luc, HLA-A2, NT-2 cell line) | Phase I/II | [101,102] |
Lactobacillus plantarum | Lactobacillus | MCF-7, MDA-MB-231, 4T1 | Colon cancer (Caco-2, BGC-823, HT-29) | [103,104] | |
Lactobacillus rhamnosus | Lactobacillus | MDA-MB-231 | Colorectal cancer (HT-29), cervical adenocarcinoma (HeLa) | [105] |
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Yaghoubi, A.; Khazaei, M.; Hasanian, S.M.; Avan, A.; C. Cho, W.; Soleimanpour, S. Bacteriotherapy in Breast Cancer. Int. J. Mol. Sci. 2019, 20, 5880. https://doi.org/10.3390/ijms20235880
Yaghoubi A, Khazaei M, Hasanian SM, Avan A, C. Cho W, Soleimanpour S. Bacteriotherapy in Breast Cancer. International Journal of Molecular Sciences. 2019; 20(23):5880. https://doi.org/10.3390/ijms20235880
Chicago/Turabian StyleYaghoubi, Atieh, Majid Khazaei, Seyed Mahdi Hasanian, Amir Avan, William C. Cho, and Saman Soleimanpour. 2019. "Bacteriotherapy in Breast Cancer" International Journal of Molecular Sciences 20, no. 23: 5880. https://doi.org/10.3390/ijms20235880